HSV

A new study finds that regular use of tenofovir gel helped reduce the risk of genital herpes acquisition in women in sub-Saharan Africa.

Varying dose levels of the GEN-003 vaccine were found to be associated with decreased viral shedding and lesion reduction at up to 1 year post-treatment.

A molecule capable of clearing HSV-1 infection in the cells of the cornea could be a promising potential option for those who have developed resistance to current drugs.

Check out the top 10 infectious disease articles of 2017.

Scientists are working on developing preventive and therapeutic strategies that target both HIV and herpes, as having herpes may make individuals more vulnerable to contracting HIV.

Having herpes simplex 2 puts individuals at greater risk of contracting HIV, and vice versa, largely due to increased genital ulceration and viral shedding.

A herpes infection leads to deadly viral meningitis in an Iowa infant, an ingestible smart pill that can remind you to take your medications, global catastrophic biological risks, whether or not you should complete the full course of antibiotics, and all you need to know about Candida auris make up this week’s Top 5 articles.

Researchers from Dartmouth College’s Geisel School of Medicine have found that pregnant women with a history of HSV-1 maintain active antibodies against the virus that can be passed on to their newborns.

In case you missed them, here are last month's Top 5 news articles from Contagion®.

In a recent study, scientists from the NIH identify a set of protein complexes that are recruited viral genes and stimulate not only initial HSV infection, but also reactivation of dormant HSV.

Researchers have discovered that women who experience active genital herpes infection early in their pregnancy may be more likely to have a child who will later be diagnosed with autism spectrum disorder.

Catch up on last month's top infectious disease news coverage from Contagion®.

Researchers have developed a new trivalent vaccine that has proven to provide powerful protection against genital herpes (HSV) in preclinical trials.

A new genital herpes drug, pritelivir, has demonstrated greater virus suppression than the present standard treatment in a clinical trial.

Although herpes remains one of the most prevalent sexually transmitted infections in the United States, the US Preventive Services Task Force is calling for less routine testing.

Technology gives men who have sex with men (MSM) new ways to assess their health status, prevent HIV and other STDs (sexually transmitted diseases), and find care.

A new technological approach to genome editing that can clear latent and productive herpesvirus infections from human cells in vitro could eventually lead to a potent prophylactic.

In a recent publication, Catherine F. Decker, MD, from Walter Reed National Military Medical Center, Bethesda, Maryland, discussed some infections that have recently emerged as important sexually transmitted diseases.

This new approach could hold promise as a novel method of vaccinating against herpes simplex-2 virus (HSV-2).

Albert Einstein College of Medicine researchers have developed a new vaccine type that shows promise to possibly become the first ever for preventing genital herpes.